GRI-0621, an experimental oral therapy for idiopathic pulmonary fibrosis (IPF), may stabilize lung function, according to an interim analysis of an ongoing Phase 2a study. Forced vital capacity (FVC), a measure of how much air a person can forcibly exhale, didn’t worsen during the first six weeks of the…
Rein Therapeutics is working with clinical sites to begin recruiting patients in the U.K. for its Phase 2 trial of LTI-03, a therapy candidate for idiopathic pulmonary fibrosis (IPF), after receiving approval from the country’s Medicines and Healthcare Products Regulatory Agency (MHRA). “This MHRA approval marks an important…
Consistently tracking the levels of Krebs von den Lungen-6 (KL-6), a protein that can indicate lung inflammation or damage, may help predict acute exacerbations in people with idiopathic pulmonary fibrosis (IPF) and other types of fibrotic interstitial lung diseases (ILDs), a study reports. Findings indicated that KL-6 levels tended…
CS014, a treatment candidate for idiopathic pulmonary fibrosis (IPF), was found to be safe and well tolerated in healthy volunteers in a Phase 1 clinical trial, according to new data from developer Cereno Scientific. Further, the experimental medication reached levels in the bloodstream that the company predicts will…
A Phase 2 clinical trial has begun recruiting that’s assessing the safety and efficacy of LTI-03, Rein Therapeutics’ inhaled therapy for idiopathic pulmonary fibrosis (IPF). RENEW (NCT06968845) is expected to enroll up to 120 people at about 50 sites in the U.S., U.K., Germany, Austria, and Poland.
GRI Bio has reached an interim enrollment goal for its Phase 2a clinical trial testing GRI-0621 — a therapy targeting natural killer T-cells (NKT cells) to treat idiopathic pulmonary fibrosis (IPF) — and expects to report initial results later this quarter, per a company press release. With…
Get regular updates to your inbox.
